Video
Pembrolizumab demonstrates efficacy as part of trimodal treatment in bladder cancer
Author(s):
Arjun V. Balar, MD, discusses notable findings from 2 separate studies of pembrolizumab (Keytruda).
In this video, Arjun V. Balar, MD, shares notable findings from the ASCO 2021 abstracts “First-line pembrolizumab (pembro) in cisplatin-ineligible patients with advanced urothelial cancer (UC): Response and survival results up to five years from the KEYNOTE-052 phase 2 study” and “Pembrolizumab (pembro) in combination with gemcitabine (Gem) and concurrent hypofractionated radiation therapy (RT) as bladder sparing treatment for muscle-invasive urothelial cancer of the bladder (MIBC): A multicenter phase 2 trial.” Balar is an associate professor of medicine at the NYU Grossman School of Medicine and genitourinary medical oncology program director at NYU Langone’s Perlmutter Cancer Center, New York.
